CARsgen Seizes China Precision Medicine Opportunity, Looks Globally

Amid China’s big push into precision medicine, the Chinese bioventure CARsgen is developing what it says is the world’s first CAR-T cell immunotherapy for liver cancer and is seeking a global partner to develop its proprietary therapies. The company is also aiming to raise additional funding to advance its pipeline.